**PRODUCT:** Concanamycin A

**ALTERNATE NAMES:** [(2R,3S,4R,6R)-6-[(2S,4R,5S)-2-[(4E,6E,14E,16Z)-11-ethyl-10,12-dihydroxy-3,17-dimethoxy-7,9,13,15-tetramethyl-18-oxo-1-oxacyclooctadeca4,6,14,16-tetraen-2-yl]-3-hydroxypentan-2-yl]-2-hydroxy-5-methyl-6-[(E)-prop-1-enyl]oxan-4-yl]oxy-4-hydroxy-2-methylxan-3-yl carbamate; Folimycin; NSC674620; Antibiotic X 4357B

**CATALOG NUMBER:** B2091-25,100

**AMOUNT:** 25 μg, 100 μg

**STRUCTURE:**

**MOLECULAR FORMULA:** C₄₆H₇₅NO₁₄

**MOLECULAR WEIGHT:** 866.09

**CAS NUMBER:** 80890-47-7

**APPEARANCE:** White lyophilized solid

**SOLUBILITY:** DMSO

**PURITY:** ≥95%

**STORAGE:** Store at -20 °C. Protect from air and moisture

**DESCRIPTION:** Concanamycin A is a specific inhibitor of V-type (vacuolar) H⁺-ATPase. It displays > 2000-fold selectivity over other H⁺-ATPases (IC₅₀ values are 9.2, > 20000, > 20000 and > 20000 nM for yeast V-type, F-type, P-type H⁺-ATPases and porcine P-type Na⁺,K⁺-ATPase respectively). Concanamycin A blocks cell surface expression of viral glycoproteins without affecting their synthesis and, at 0.8 μM, prevents entry of influenza virus into cells. It also blocks cell surface expression of viral glycoproteins without affecting their synthesis.


**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**RELATED PRODUCTS:**
- Bafilomycin A1 (Cat. No. 1829-50, 250)
- (+)-Blebbistatin (Cat. No. 2407-1, 5)
- (±)-Blebbistatin (Cat. No. 2405-5, 25)
- (-)-Blebbistatin (Cat. No. 2406-1, 5)
- Bufalin (Cat. No. 2509-10, 50)
- Concanamycin A (Cat. No. B2091-25,100)
- Ouabain (Cat. No. B2068-10, 50)

**USAGE:** FOR RESEARCH USE ONLY! Not to be used in humans